Stock VRCA VERRICA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
7.26 USD +7.40% Intraday chart for Verrica Pharmaceuticals Inc. +5.68% -0.82%
03-26 Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing MT
03-26 Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services
Ligand Pharma's at-home skin treatment gets FDA approval
Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy
Verrica Pharmaceuticals Doses Last Patient in Part 2 of Phase 2 Study of Potential Skin Cancer Treatment
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH?? for the Treatment of Common Warts
Verrica Pharmaceuticals Partners With Walgreens to Distribute YCANTH Therapy
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH?
Sector Update: Health Care Stocks Retreating Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises
Verrica Pharmaceuticals Inc. Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma At the American Academy of Dermatology 2023 Innovation Academy Meeting
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRCA Stock
  4. News Verrica Pharmaceuticals Inc.
  5. Other languages